For women who have considered hormone therapy for menopause, there’s some big news, according to the New York Times. In November, the Food and Drug Administration (FDA) announced a major change to the labeling of hormone treatments. Within the next six months, the agency plans to remove the longstanding “black box” warning from estrogen-containing hormone products, according to FDA Commissioner Dr. Marty Makary.

The updated labels will instead include age-specific recommendations, reflecting newer evidence that hormone therapy may offer long-term health benefits when initiated within 10 years of menopause. This shift represents a dramatic departure from the messaging in place since 2003, when the Women’s Health Initiative (WHI) trials linked certain hormone formulations to elevated risks of heart disease, blood clots, stroke and breast cancer.

A Significant Reversal in Federal Guidance

The original black box warnings were added after WHI researchers concluded that oral estrogen plus progestin increased the risk of breast cancer and blood clots, and that hormone therapy did not protect against heart disease or dementia in older women. Those findings triggered a steep drop in hormone therapy use across the U.S., with physicians hesitant to prescribe the treatments and patients hesitant to start hormone therapy, even when experiencing disruptive menopausal symptoms like hot flashes, night sweats or sleep problems.

Dr. Makary argued in November that the risks of hormone therapy have been overstated and that benefits – including better cardiovascular health, reduced cognitive decline, and improved bone density – have been underappreciated for women who begin therapy near the onset of menopause.

He stated that MHT “may improve health outcomes at a population level more than almost any intervention except antibiotics or vaccines.”

Why the FDA Is Changing the Warning

The new guidance will include age-specific recommendations, emphasizing that hormone therapy started within 10 years of menopause may have long-term health benefits. These benefits can include supporting heart health, maintaining bone strength and reducing the risk of osteoporosis and protecting brain health

Dr.  Makary says the benefits of early hormone therapy have been underappreciated, and that women shouldn’t avoid treatment out of fear.

Critics Push Back

Some experts strongly disagree with the FDA’s decision. Critics say that:

  • The evidence supporting a label change is not strong enough.
  • The FDA should have convened an independent scientific advisory committee before acting.
  • Moving warnings into lengthy package inserts may make risks less visible to patients.

Dr. Diana Zuckerman, president of the National Center for Health Research, warned that removing the black box risks “taking women’s health backward,” arguing that many safer, evidence-backed methods exist for reducing heart disease, dementia, cancer, and osteoporosis risk.

What the Research Actually Shows

The WHI trials found:

  • Estrogen + progestin oral therapy increased breast cancer risk. But the danger to women was small, especially in early menopause.
  • Estrogen-only therapy did not increase breast cancer risk and was associated with a lower heart attack risk in women in their 50s.
  • Both regimens raised risks of stroke and blood clots – but mainly in older women starting therapy many years after menopause.
  • Hormone therapy reduced fractures and colorectal cancer risk.

Many menopause experts have long argued that the WHI population – women aged 50–79, many far beyond menopause – did not reflect real-world use among newly menopausal women.

Why the Decision Matters

For decades, doctors were urged to prescribe hormone therapy sparingly and only for short-term symptom relief. But new FDA language is expected to encourage more individualized treatment decisions and reduce stigma around using hormone therapy, making it easier for women to access safe, effective treatments for menopause without fear of harmful side effects.

In addition, many clinicians have argued that vaginal estrogen products—which have minimal systemic absorption—should never have carried a black box warning. The upcoming label changes will apply to all estrogen-containing products, including these low-dose local therapies.

The Bottom Line for Patients

Hormone therapy can safely relieve symptoms and support long-term health – especially if started early. But, it’s not for everyone, particularly those who have a history of breast cancer, a history of blood clots or stroke or certain liver or heart conditions.

If you have questions about hormone replacement therapy for relief from the symptoms of perimenopause and menopause, contact Renuva HRT & Wellness to schedule a consultation to see if you’re a candidate for treatment.

Source: https://www.nytimes.com/2025/11/10/health/fda-hormone-replacement-menopause.html 

One Comment

  1. Jaimcy George April 7, 2026 at 7:49 pm - Reply

    Hi I wanted see that u prescribe progesterone torches ?

Leave A Comment